Simplified Rapid Hydration in Preventing CA-AKI Among Patients With Chronic Kidney Disease
NCT ID: NCT02232997
Last Updated: 2022-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1002 participants
INTERVENTIONAL
2015-04-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis
NCT02225431
Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension
NCT07033260
To Compare Intravenous and Oral Hydration of the Prevention for CIN in Elderly Patients Undergoing Intravenous CECT
NCT03872739
Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease
NCT05283512
Circulatory Management and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy
NCT02803372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Hydration
Standard long-term hydration, i.e. hydrated with normal saline 12 hours before and 12 hours after coronary intervention at a rate of 1 ml/kg/h
Standard Hydration
Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
Simplified Hydration
Rapid short-term hydration, i.e. hydrated with normal saline from 1 hour before to 4 hours after coronary intervention at a rate of 3 ml/kg/h
Simplified Hydration
Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Hydration
Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
Simplified Hydration
Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent;
* Candidates scheduled for coronary intervention (angiography and/or coronary intervention);
* Patients with chronic renal insufficiency, the baseline estimated glomerular filtration rate (eGFR) was 15-60 mL/min / 1.73 m²
* At least one risk factor (age\>75 years, medical history of diabetes mellitus or hypertension, congestive heart failure \[NYHA class \>II or history of acute pulmonary edema\]);
Exclusion Criteria
* History of exposure to contrast medium or acute infectious diseases within 48 hours prior to the procedure;
* Acute decompensated heart failure;
* Left ventricular thrombus;
* Allergy to contrast agent;
* Pregnancy or lactation;
* Malignant tumour or life expectancy \<1 year;
* Pre-procedural receipt of NSAIDs (except Asprin), aminoglycosides, cyclosporine or cisplatin in the past 48 h;
* Severe valve disease or elective undergoing surgery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University First Hospital
OTHER
Fudan University
OTHER
The General Hospital of Northern Theater Command
OTHER
Xiamen Cardiovascular Hospital, Xiamen University
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Sichuan Provincial People's Hospital
OTHER
Wuhan Asia Heart Hospital
OTHER
West China Hospital
OTHER
Jining Medical University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Fujian Provincial Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Fuling Central Hospital of Chongqing City
OTHER
Second Xiangya Hospital of Central South University
OTHER
People's Hospital of Guangxi Zhuang Autonomous Region
OTHER
Maoming People's Hospital
OTHER
Xijing Hospital
OTHER
Beijing Friendship Hospital
OTHER
Tangshan Gongren Hospital
OTHER
Xuzhou Central Hospital
OTHER
Southern Medical University, China
OTHER
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiyan Chen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiyan Chen, MD
Role: STUDY_CHAIR
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital
Yong Liu, MD
Role: STUDY_DIRECTOR
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital
Yong Huo, MD
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Junbo Ge, MD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Pingyan Chen, MS
Role: PRINCIPAL_INVESTIGATOR
Southern Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSC20140818
Identifier Type: OTHER
Identifier Source: secondary_id
CSC20140818
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.